The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Boyiadzis, Michael; Bishop, Michael; Abonour, Rafat; Anderson, Kenneth C.; Ansell, Stephen M.; Avigan, David; Barbarotta, Lisa; Barrett, A. John; Besien, Koen van; Bergsagel, P. Leif; Borrello, Ivan; Brody, Joshua; Brufsky, Jill; Cairo, Mitchell S.; Chari, Ajai; Cohen, Adam D.; Cortes, Jorge; Forman, Stephen J.; Friedberg, Jonathan W.; Fuchs, Ephraim J.; Gore, Steven D.; Jagannath, Sundar; Kahl, Brad S.; Kline, Justin; Kochenderfer, James N.; Kwak, Larry W.; Levy, Ronald; Lima, Marcos de; Litzow, Mark R.; Mahindra, Anuj; Miller, Jeffrey S.; Munshi, Nikhil C.; Orłowski, Robert Z.; Pagel, John M.; Porter, David; Russell, Stephen J.; Schwartz, Karl; Shipp, Margaret A.; Siegel, David S.; Stone, Richard; Tallman, Martin S.; Timmerman, John M.; Rhee, Frits van; Waller, Edmund K.; Welsh, A; Werner, Michael; Wiernik, Peter H.; Dhodapkar, Madhav V.

doi:10.1186/s40425-016-0188-z

Cited by 19 publications

(21 citation statements)

References 222 publications

(187 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab, usually given in combination with cytotoxic chemotherapy, has dramatically improved outcomes in indolent 29 and aggressive Bcell lymphomas 30 and is now part of standard front-line therapy. Further agents including depleting antibodies, radio-immune conjugates, bi-specific T-cell engagers and other modalities have also proven effective and are in widespread use 31…”

Section: Discussionmentioning

confidence: 99%

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Maciocia¹,

Wawrzyniecka²,

Philip³

et al. 2017

Nat Med

222

187

View full text Add to dashboard Cite

Mature T cell cancers are typically aggressive, treatment resistant and associated with poor prognosis. Clinical application of immunotherapeutic approaches has been limited by a lack of target antigens that discriminate malignant from healthy (normal) T cells. Unlike B cell depletion, pan-T cell aplasia is prohibitively toxic. We report a new targeting strategy based on the mutually exclusive expression of T cell receptor β-chain constant domains 1 and 2 (TRBC1 and TRBC2). We identify an antibody with unique TRBC1 specificity and use it to demonstrate that normal and virus-specific T cell populations contain both TRBC1 and TRBC2 compartments, whereas malignancies are restricted to only one. As proof of concept for anti-TRBC immunotherapy, we developed anti-TRBC1 chimeric antigen receptor (CAR) T cells, which recognized and killed normal and malignant TRBC1, but not TRBC2, T cells in vitro and in a disseminated mouse model of leukemia. Unlike nonselective approaches targeting the entire T cell population, TRBC-targeted immunotherapy could eradicate a T cell malignancy while preserving sufficient normal T cells to maintain cellular immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Maciocia¹,

Wawrzyniecka²,

Philip³

et al. 2017

Nat Med

222

187

View full text Add to dashboard Cite

show abstract

“…Recent US Food and Drug Administration approval for refractory DLBCL based on the results of the ZUMA-1 study shows that CAR T-cell therapy will be used in refractory DLBCL in the future. 94 , 95 Clinical trials with CAR therapy are ongoing in indolent lymphomas (including marginal zone lymphoma) at this time.…”

Section: Future Strategiesmentioning

confidence: 99%

Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment

et al. 2018

View full text Add to dashboard Cite

Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma and represents a wide spectrum of disease, ranging from indolent low-grade marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma to aggressive diffuse large B-cell lymphoma. The PGL is a relatively rare cancer and easily misdiagnosed due to its unspecific symptoms of the digestive tract. The medical literature and ongoing clinical trials were reviewed on the clinical presentation, diagnosis, prognosis, prevention, and treatment of PGL. Primary gastric lymphoma is an event in the course of cancer with a variable clinical presentation and a wide differential diagnosis. Chronic gastritis secondary to Helicobacter pylori (H pylori) infection has been considered a major predisposing factor for MALT lymphoma. Magnetic resonance imaging and endoscopic ultrasonography have helped in staging of these cancers. The clinical course and prognosis of this disease are dependent on histopathological subtype and stage at the time of diagnosis. A global therapeutic approach to the cure of PGL has completely changed over the past 10 years, including innovative and conservative options to reduce treatment toxicity. Due to the rarity of PGL, many aspects of this neoplasm are still controversial. The incidence of this disease is increasing, making it necessary for clinicians to understand the clinical symptoms, workup, and treatment of these lymphomas.

show abstract

“…The antitumor activity of rituximab is believed to be mediated in part by antibody-dependent cellular cytotoxicity (ADCC) (1). However, a substantial proportion of patients develop resistance to treatment, underscoring the need for more effective strategies (1)(2)(3). A variety of immunotherapeutic approaches including 4-1BB/CD137, programmed death 1 (PD-1), and PD-ligand 1 (PD-L1) targeted antibodies, as well as bispecific antibodies and chimeric antigen receptor (CAR) T cells are currently under investigation in patients with NHL and other hematological malignancies (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Gopal

Levy²,

Houot

et al. 2020

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Prior studies have shown that 4-1BB/CD137 agonistic antibodies can deliver costimulatory signals, enhancing antibody-dependent cellular cytotoxicity and potentially eliciting T-cell mediated antitumor immune responses. To evaluate new treatment strategies for relapsed/refractory disease after rituximab therapy, patients with follicular lymphoma (FL) and other CD20 + relapsed/refractory non-Hodgkin lymphomas (NHLs) were treated with the anti-4-1BB/CD137 antibody utomilumab and rituximab. Utomilumab has previously demonstrated a well-tolerated safety profile and antitumor activity as monotherapy or in combination with the anti-programmed death 1 (PD-1) antibody pembrolizumab in patients with advanced solid tumors. In this phase I study, combined treatment with utomilumab plus rituximab showed a favorable safety profile and clinical activity in patients with relapsed/refractory FL and other CD20 + NHLs.

show abstract

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Cited by 19 publications

References 222 publications

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Contact Info

Product

Resources

About